gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by Lonza Group

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): NILK-2301

            Therapeutic Area: Oncology Product Name: NILK-2301

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: LamKap Bio Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 18, 2020

            Details:

            Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Lenzilumab

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Humanigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 15, 2020

            Details:

            Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): KSI-301

            Therapeutic Area: Ophthalmology Product Name: KSI-301

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kodiak Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 27, 2020

            Details:

            Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading ophthalmic therapeutic candidate KSI-301 with a capacity to supply millions of doses per year.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Abelacimab

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Anthos Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 11, 2020

            Details:

            The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Wnt Activating Antibodies

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Surrozen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 29, 2020

            Details:

            Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 01, 2020

            Details:

            Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Oxypurinol

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xortx Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 30, 2020

            Details:

            Lonza Pharma will be resposible for manufacturing of active pharmaceutical ingredient for XRx-101 and XRx-008 in response to support the drug development and clinical trial process for COVID-19.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): TAC01-HER2

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Triumvira Immunologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 24, 2020

            Details:

            Collaboration, aimed at developing Triumvira’s TAC01-HER2 T-cell therapy for solid tumors, will leverage Lonza’s expertise in process development and the usage of its proprietary Cocoon® Platform.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): RP-L201

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Recipient: Rocket Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Partnership January 30, 2020

            Details:

            The agreement covers development and manufacturing of RP-L201, a phase 1/2 candidate for the treatment of Leukocyte Adhesion Deficiency-I (LAD-I).